Intervention

Fulvestrant Injectable Product

ClinicalTrials.gov intervention label

Clinical trials3

Recruiting0

Common conditions8

Lead sponsors shown3

Clinical trials

3 shown

Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)NCT06525675 · 2022-07-18

Palbociclib in Combination With Fulvestrant Versus Fulvestrant in Advanced Breast Cancer: A Real-world Study in ChinaNCT04526028 · 2019-09-13

PAlbociclib and Circulating Tumor DNA for ESR1 Mutation DetectionNCT03079011 · 2017-03-22

Common conditions

Metastatic Breast Cancer2 Advanced Breast Cancer1 Breast Cancer1 ER-positive Breast Cancer1 Fulvestrant1 HER2-negative Breast Cancer1 Luminal Breast Cancer1 Palbociclib1

Leading sponsors

MedSIR1 Tianjin Medical University Cancer Institute and Hospital1 UNICANCER1

Trial status mix

COMPLETED2

UNKNOWN1

Phase mix

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.